Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (33)

2022

  1. A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β

    Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157

  2. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

    Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100

  3. Multidisciplinary Consensus for the Management of Pulmonary Thromboembolism

    Archivos de Bronconeumologia

  4. SEA 2022 Standards for Global Control of Cardiovascular Risk

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

  5. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. Activation-induced deaminase is critical for the establishment of DNA methylation patterns prior to the germinal center reaction

    Nucleic Acids Research, Vol. 49, Núm. 9, pp. 5057-5073

  2. Multidisciplinary consensus for the management of pulmonary thromboembolism

    Archivos de Bronconeumologia

  3. PICO questions and DELPHI methodology for the management of venous thromboembolism associated with COVID-19

    Viruses, Vol. 13, Núm. 11

2020

  1. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry

    European heart journal, Vol. 41, Núm. 18, pp. 1720-1729

  2. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: The BACS score

    European Respiratory Journal, Vol. 56, Núm. 6

  3. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature

    Amyloid, Vol. 27, Núm. 3, pp. 163-167

2019

  1. Long-term engraftment of human cardiomyocytes combined with biodegradable microparticles induces heart repair

    Journal of Pharmacology and Experimental Therapeutics, Vol. 370, Núm. 3, pp. 761-771

  2. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

  3. Standards for global cardiovascular risk management arteriosclerosis

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 1-43

2018

  1. Cancer-associated thrombosis: Beyond clinical practice guidelines-A multidisciplinary (SEMI-SEOM-SETH) expert consensus

    TH Open, Vol. 2, Núm. 4, pp. e373-e386

2017

  1. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes

    Cancer Letters, Vol. 409, pp. 42-48

  2. FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

    Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009

2016

  1. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136

  2. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

2015

  1. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: A practical approach

    Clinical and Applied Thrombosis/Hemostasis, Vol. 21, Núm. 4, pp. 297-308